Start with the surprising number: for roughly a decade, 'CRISPR' effectively meant one enzyme, Cas9. By 2025, a growing share of new gene-editing filings were about something else entirely. The monoculture is breaking up.
The clearest signal is the rise of alternative enzyme families. Caribou Biosciences' publication US20250325698A1 covers therapeutic applications of CRISPR Type V systems — a different class of cutter from Cas9, with different properties. Its companion US20250027078A1 covers DNA-containing guides for those Type V systems.
Editing modes are diversifying too. Publication US20250243482A1 covers Class 2 Type V CRISPR-Cas prime editing — merging the newer prime-editing approach with a non-Cas9 enzyme. Three or more distinct technical directions in one year is a real trend, not noise.
The foundational owner is still present. The Broad Institute's grant US12305204B2 on CRISPR enzymes and systems shows the platform's anchor estate continued issuing in 2025 — the base layer didn't shrink even as the field broadened on top of it.
What does the diversification mean? In plain terms, different enzymes have different strengths — size, precision, the sequences they can reach. A field that has only Cas9 is limited to what Cas9 can do. A field with Type V enzymes, prime editors, and new guides can attack more diseases. The patent spread is a map of that expanding reach.
By the numbers, 2025 is the year the CRISPR patent story stopped being a single-enzyme story. Foundational claims still anchor it, but the growth is in the alternatives — and that breadth, not any one tool, is what the filings now point to.